Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 09 04 2018
revised: 18 07 2018
accepted: 27 07 2018
pubmed: 20 9 2018
medline: 22 5 2019
entrez: 20 9 2018
Statut: ppublish

Résumé

Deciphering the underlying genetic basis behind pancreatic cancer (PC) and its associated multimorbidities will enhance our knowledge toward PC control. The study investigated the common genetic background of PC and different morbidities through a computational approach and further evaluated the less explored association between PC and autoimmune diseases (AIDs) through an epidemiological analysis. Gene-disease associations (GDAs) of 26 morbidities of interest and PC were obtained using the DisGeNET public discovery platform. The association between AIDs and PC pointed by the computational analysis was confirmed through multivariable logistic regression models in the PanGen European case-control study population of 1,705 PC cases and 1,084 controls. Fifteen morbidities shared at least one gene with PC in the DisGeNET database. Based on common genes, several AIDs were genetically associated with PC pointing to a potential link between them. An epidemiologic analysis confirmed that having any of the nine AIDs studied was significantly associated with a reduced risk of PC (Odds Ratio (OR) = 0.74, 95% confidence interval (CI) 0.58-0.93) which decreased in subjects having ≥2 AIDs (OR = 0.39, 95%CI 0.21-0.73). In independent analyses, polymyalgia rheumatica, and rheumatoid arthritis were significantly associated with low PC risk (OR = 0.40, 95%CI 0.19-0.89, and OR = 0.73, 95%CI 0.53-1.00, respectively). Several inflammatory-related morbidities shared a common genetic component with PC based on public databases. These molecular links could shed light into the molecular mechanisms underlying PC development and simultaneously generate novel hypotheses. In our study, we report sound findings pointing to an association between AIDs and a reduced risk of PC.

Identifiants

pubmed: 30229903
doi: 10.1002/ijc.31866
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1540-1549

Informations de copyright

© 2018 UICC.

Auteurs

Paulina Gomez-Rubio (P)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Janet Piñero (J)

Research Program on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (IMIM), Universidad Pompeu Fabra (UPF), Barcelona, Spain.

Esther Molina-Montes (E)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Alba Gutiérrez-Sacristán (A)

Research Program on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (IMIM), Universidad Pompeu Fabra (UPF), Barcelona, Spain.

Mirari Marquez (M)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Marta Rava (M)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Christoph W Michalski (CW)

Department of Surgery, Technical University of Munich, Munich, Germany.
Department of Surgery, University of Heidelberg, Heidelberg, Germany.

Antoni Farré (A)

Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Xavier Molero (X)

Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Hospital Universitaru Vall d'Hebron, Exocrine Pancreas Research Unit and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Universitat Auntònoma de Barcelona, Campus de la UAB, Barcelona, Spain.

Matthias Löhr (M)

Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and University Hospital, Stockholm, Sweden.

José Perea (J)

Department of Surgery, University Hospital 12 de Octubre, Madrid, Spain.

William Greenhalf (W)

Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United Kingdom.

Michael O'Rorke (M)

Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

Adonina Tardón (A)

Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Department of Medicine, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.

Thomas Gress (T)

Department of Gastroenterology, University Hospital of Giessen and Marburg, Marburg, Germany.

Victor M Barberá (VM)

Laboratorio de Genética Molecular, Hospital General Universitario de Elche, Elche, Spain.

Tatjana Crnogorac-Jurcevic (T)

Centre for Molecular Oncology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Luís Muñoz-Bellvís (L)

General and Digestive Surgery Department, Hospital Universitario de Salamanca, Salamanca, Spain.

Enrique Domínguez-Muñoz (E)

Department of Gastroenterology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

Joaquim Balsells (J)

Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Hospital Universitaru Vall d'Hebron, Exocrine Pancreas Research Unit and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Universitat Auntònoma de Barcelona, Campus de la UAB, Barcelona, Spain.

Eithne Costello (E)

Department of Molecular and Clinical Cancer Medicine, The Royal Liverpool University Hospital, Liverpool, United Kingdom.

Jingru Yu (J)

Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and University Hospital, Stockholm, Sweden.

Mar Iglesias (M)

Department of Gastroenterology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain.

Lucas Ilzarbe (L)

Department of Gastroenterology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain.

Jörg Kleeff (J)

Department of Surgery, Technical University of Munich, Munich, Germany.
Department of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, Halle, (Saale), Germany.

Bo Kong (B)

Department of Surgery, Technical University of Munich, Munich, Germany.

Josefina Mora (J)

Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Liam Murray (L)

Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.

Damian O'Driscoll (D)

Cancer Data Registrars, National Cancer Registry Ireland, Cork, Ireland.

Ignasi Poves (I)

Department of Gastroenterology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain.

Rita T Lawlor (RT)

ARC-Net Centre for Applied Research on Cancer, Department of Pathology and Diagnostics, University Hospital Trust of Verona, Verona, Italy.

Weimin Ye (W)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet and University Hospital, Sweden.

Manuel Hidalgo (M)

Hospital Madrid-Norte-Sanchinarro and Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Rosenberg Clinical Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Aldo Scarpa (A)

ARC-Net Centre for Applied Research on Cancer, Department of Pathology and Diagnostics, University Hospital Trust of Verona, Verona, Italy.

Linda Sharp (L)

Cancer Data Registrars, National Cancer Registry Ireland, Cork, Ireland.
Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom.

Alfredo Carrato (A)

Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Department of Oncology, Hospital Ramón y Cajal, Madrid, Spain.

Francisco X Real (FX)

Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.

Laura I Furlong (LI)

Research Program on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (IMIM), Universidad Pompeu Fabra (UPF), Barcelona, Spain.

Núria Malats (N)

Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Center CNIO, Madrid, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Enfermedades Hepáticas y Digestivas (CIBERHD), and Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
PanGenEU Study Investigators (Additional file 1: Annex S1).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH